Researchers from Bengbu Medical College have discovered new derivatives of honokiol, a biphenyl neolignan extracted from Magnolia species, which has been shown to possess pharmacological properties, including anticancer, anti-inflammatory, antioxidant, anti-infectious and neuroprotective activities. A total of 21 new honokiol derivatives were synthesized, with derivative [I] being selected as the lead with the most potent in vitro cytotoxic activity.
Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.
A new method of CAR T-cell immunotherapy developed by researchers at the University of Pennsylvania Perelman School of Medicine could serve as a treatment for most blood cancers. Until now, CAR T-based immunotherapy for hematological malignancies has targeted the antigens CD19 for B cells, CD7 for T cells, BCMA for myeloma, and CD33 for AML.
Leucid Bio Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to commence a phase I/II trial of LEU-011 for the treatment of adults with relapsed or refractory solid tumors.
Recludix Pharma Inc. has divulged signal transducer and activator of transcription 3 (STAT3) and 6 (STAT6) inhibitors reported to be useful for the treatment of cancer and inflammation.
Tegid Therapeutics Inc. has identified proteolysis targeting chimera (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)-targeting moiety.
Researchers from University Hospital Basel and Universitätsklinikum Ulm presented the discovery of novel radiotheragnostic candidates targeting C-X-C chemokine receptor 4 (CXCR4), which is highly expressed in various cancers and has been linked to poor prognosis.
Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
Orionis Biosciences BV has established a multiyear collaboration with Genentech Inc., a member of the Roche Group, to discover novel small-molecule molecular glues for targets in major disease areas, including oncology and neurodegeneration.
RSS
